Pfizer Stock

Pfizer Debt

The Debt of Pfizer (PFIZER.NS) as of Aug 10, 2026 is -3.90 B INR. In the previous year, Debt was -220.50 M INR — a change of 1,667.12% (lower).

Debt

-3.90 BINR

YoY

1,667.12%

Last updated:

In 2026, Pfizer's total debt was -3.90 B INR, a 1,667.12% change from the -220.50 M INR total debt recorded in the previous year.

Access this data via the Eulerpool API

Pfizer Stock analysis

What does Pfizer do? Pfizer Ltd is a global biopharmaceutical company based in New York City, USA. The company was founded in 1849 by cousins Charles Pfizer and Charles Erhart, and has achieved numerous milestones in the pharmaceutical industry during its 170-year history. Pfizer's business model is based on the research, development, production, and distribution of innovative drugs and vaccines for a variety of diseases. With a diverse portfolio of products, the company's range extends from drugs for cancer, inflammation, and immunology to neurological and cardiology conditions. Pfizer is a global leader in the development of cancer drugs and has achieved groundbreaking research successes in recent years. Key divisions of the company include oncology, pain management, cardiology, and neurology. Pfizer places great emphasis on putting patients and their needs at the center and works closely with medical professionals, patient groups, and authorities to ensure the best possible patient care. Pfizer is a leading provider of vaccines and has achieved significant breakthroughs in the development of COVID-19 vaccines in recent years. In December 2020, the company was one of the first worldwide to bring a vaccine against the coronavirus to market, making a significant contribution to the fight against the pandemic. In addition to drug research and development, Pfizer is also heavily involved in corporate social responsibility. The company is committed to sustainable development and continuously works to reduce its carbon footprint. The Pfizer Foundation also supports numerous nonprofit organizations and projects in the areas of health, education, and environmental protection. Among Pfizer's most well-known products are medications such as Viagra, Lipitor, and Lyrica, as well as the COVID-19 vaccine Comirnaty. Pfizer has offices in over 150 countries and employs over 90,000 people worldwide. Like any global company, Pfizer faces challenges. The company is often criticized for high drug prices and the availability of medications in developing countries. However, Pfizer actively advocates for access to affordable healthcare and delivers drugs and vaccines to all regions of the world. Overall, Pfizer is a company of great importance in the global healthcare industry. Through its research and development of innovative drugs and vaccines, the company contributes to improving the quality of life for millions of people worldwide. Pfizer is one of the most popular companies on Eulerpool.

Debt Details

Understanding Pfizer's Debt Structure

Pfizer's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Pfizer's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Pfizer’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Pfizer’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Pfizer stock

Debt of Pfizer is -3.90 B INR in 2026.

Debt of Pfizer changed from -220.50 M INR to -3.90 B INR, representing a 1,667.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Pfizer since 2006 – with annual values, charts, and detailed analysis.

Debt's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Pfizer historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Pfizer

All Key Metrics — Pfizer